Friday, June 28, 2013

Pfizer Skelaxin to face competion from generic copies

Amneal Pharma the 7th largest generic drug manufacturer in the US drug market has received ANDA approval for generic Skelaxin (metaxalone). Pfizer generated $220m in annual sales in the US in 2012 from Skelaxin. Generic copies of Skelaxin are available at a 25 percent discount.  Assuming a 40 percent market share for Amneal, Skelaxin sales should drop significantly going forward.  Skelaxin sales have grown 10 percent year over year in 2012.

Sandoz is the other generic player with an approval for metaxalone generics, however soon after approval Sandoz had to discontinue the supply of metaxalone generics

Enter your email address:


Delivered by FeedBurner